Dazi

Quick links to important sections

Dazi

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dazi

Understanding Dazi

Dazi is a pharmacological treatment categorized as a selective phosphodiesterase type 5 (PDE5) inhibitor. It is primarily utilized in the management of erectile dysfunction (ED), a condition characterized by the consistent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance.

Mechanism of Action

The therapeutic effect of Dazi is centered on its ability to regulate blood flow. During sexual stimulation, the body releases nitric oxide, which triggers the production of cyclic guanosine monophosphate (cGMP). This molecule is responsible for relaxing the smooth muscle tissues within the corpora cavernosa of the penis, allowing for increased blood inflow.

Dazi works by inhibiting the PDE5 enzyme, which is responsible for the degradation of cGMP. By preventing this breakdown, the medication helps maintain higher levels of cGMP, thereby supporting the physiological process required to achieve an erection. It is important to note that Dazi does not initiate an erection independently; natural sexual arousal and stimulation are necessary for the medication to be effective.

Clinical Application

While its most common application is for erectile dysfunction, PDE5 inhibitors like Dazi are also sometimes utilized in the management of other vascular-related conditions. The medication aims to restore a natural response to stimulation rather than acting as a stimulant or increasing libido.

Pharmacological Profile

Dazi is designed for oral administration and is absorbed into the bloodstream to act systemically. Its duration of action and onset time depend on individual metabolic factors and the specific formulation of the compound. As with any medication in this class, it interacts with the vascular system to modify blood pressure dynamics specifically within localized tissues.

What side effects are possible with Dazi?

Official Adverse Reactions and Safety Profile

The possible adverse reactions associated with Dazi (Azithromycin) are formally documented and classified according to frequency and the body's system-organ classes, as defined by regulatory authorities like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Commonly Documented Adverse Reactions

The most frequently reported side effects, classified as Very Common or Common in official labeling, primarily affect the Gastrointestinal system and include diarrhea, abdominal pain, nausea, and vomiting. Headache is also commonly listed.

Serious Adverse Reactions (Label-Documented)

Specific, rare, but clinically significant events are highlighted in regulatory safety information. These include a serious risk to the Cardiovascular system, specifically QT interval prolongation leading to the possibility of Torsade de Pointes and ventricular arrhythmias. Severe Hepatobiliary events, such as hepatitis and potentially fatal hepatic failure, are also documented safety concerns. Furthermore, rare but serious Hypersensitivity reactions, including Stevens-Johnson Syndrome (SJS) and DRESS syndrome, are noted, with regulatory documents stating these may have a delayed onset or recur.

Population-Specific Safety Considerations

Regulatory labeling establishes constraints for specific populations. Use is avoided or requires caution in patients with known severe hepatic impairment due to the drug’s primary elimination route. Caution is also advised when administering to patients with severe renal impairment and to older adults, who may be more susceptible to the cardiac risk of QT prolongation.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Dazi (Azithromycin) requires immediate medical attention due to the potential for serious complications. Documented clinical presentations of overdosage are typically similar to the adverse reactions experienced at normal therapeutic doses, primarily involving acute gastrointestinal upset such as severe nausea, vomiting, diarrhea, and abdominal pain.

However, the paramount concern in cases of overdosage is the drug's effect on the cardiovascular system. Azithromycin carries a documented risk for the prolongation of the QT interval, which can lead to life-threatening ventricular arrhythmias. The most severe potential outcome listed in regulatory documents is Torsades de pointes, a type of serious, life-threatening cardiac arrhythmia that necessitates urgent intervention.

Therefore, when overdosage is suspected, immediate medical attention is indicated. Management should consist of general symptomatic and supportive measures, as no specific antidote is known for Azithromycin overdosage. Due to the high risk of serious cardiac effects, close patient observation and continuous cardiac monitoring (ECG) are required components of the officially defined supportive treatment regimen to manage the severe systemic effects.

Therapeutic Uses of Dazi

Quick Facts: Uses of Dazi

Therapeutic Domain Conditions Addressed
Infectious Disease Management of respiratory tract infections
Dermatology Treatment of skin and soft tissue infections
Urogenital Health Addressing certain sexually transmitted infections

Dazi is a therapeutic agent used in the management of a range of conditions caused by susceptible bacteria. Its main clinical application involves providing relief for bacterial infections affecting the respiratory system, which may include chest infections like bronchitis and pneumonia, or ear and throat concerns such as tonsillitis and sinusitis.

The medication also serves a purpose in addressing bacterial infections of the skin and underlying soft tissues. Furthermore, Dazi is used within the established therapeutic protocols for certain sexually transmitted infections. Its goal is to stop bacterial growth, which then allows for the resolution of the infection.

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents (over 45 kg) are generally eligible for use under standard labeled conditions. Pediatric patients 6 months of age and older are eligible for specific labeled indications.
Populations for whom use is not recommended Pregnant and breastfeeding individuals; use is only after careful benefit/risk assessment. Patients with pneumonia who are inappropriate for oral therapy due to moderate-to-severe illness or risk factors.
Populations for whom use is contraindicated Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibiotic. Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin.

Age-Related Eligibility Rules

  • Infants (Under 6 months): Safety and effectiveness have not been established for most indications.
  • Children (Under 45 kg): Tablets and capsules are not suitable; oral suspension is required, with dosage based on body weight.
  • Older Adults (Geriatric): Eligible for use, but caution is advised due to increased susceptibility to heart rhythm changes.

Condition-Specific Eligibility Rules

  • Cardiovascular Conditions: Use is restricted and requires caution in patients with known QT interval prolongation, severe bradycardia, or uncompensated heart failure.
  • Hepatic Impairment: Dazi is contraindicated in patients with a history of azithromycin-associated liver dysfunction. Caution is necessary for patients with impaired hepatic function.
  • Renal Impairment: Caution is advised in patients with severe renal impairment (GFR < 10 space mL/min).

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in any patient with a history of macrolide hypersensitivity or azithromycin-associated liver damage.
  • Safety and effectiveness are not established for infants under 6 months of age.
  • Caution is officially required in high-risk patients with specific cardiac issues or severe organ impairment.

Connection to the overall eligibility profile: Regulatory documents strictly define eligibility based on the patient's medical history and current physiological status, establishing absolute prohibitions for past hypersensitivity or prior liver reaction, and mandating caution for populations with specific cardiac or organ-function risks. Age minimums are established for pediatric use, with safety officially not established below set thresholds.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Dazi (Azithromycin) based on several key mechanisms and documented clinical outcomes. The drug is stated to be a P-glycoprotein (P-gp) inhibitor, which can lead to increased serum levels of co-administered P-gp substrates, such as Digoxin and Colchicine. This requires specific consideration during use.

Official Restrictions and Monitoring

The co-administration of Azithromycin with Pimozide is restricted due to the potential for significantly increased plasma levels of Pimozide and an associated risk of QT interval prolongation (cardiac arrhythmia). Concomitant use with Ergot Derivatives is officially not recommended due to the theoretical risk of ergotism.

Post-marketing reports indicate a risk of potentiated anticoagulation when Azithromycin is used with coumarin-type oral anticoagulants like Warfarin, necessitating laboratory monitoring of coagulation times. The drug’s interaction with the hepatic Cytochrome P450 (CYP) system is officially documented as not being clinically significant, with no alteration of plasma levels observed for agents such as Atorvastatin.

Timing and Exposure Alterations

Administration of Azithromycin and Antacids containing aluminum or magnesium must be separated by at least two hours, as simultaneous intake reduces the antibiotic's peak plasma concentration. Pharmacokinetic studies show that co-administration with Nelfinavir results in a substantial increase in Azithromycin's overall systemic exposure. Additionally, in patients with severe renal impairment, systemic exposure to Azithromycin is significantly increased.

Mechanism of Action

Direct Inhibition of Bacterial Protein Synthesis

The primary mechanism of Dazi (Azithromycin) involves highly specific binding to the bacterial 50S ribosomal subunit . This molecular interaction physically obstructs the mRNA exit tunnel, immediately halting the elongation of the nascent peptide chain and arresting the protein translation pathway. This interruption prevents the bacteria from building essential components for growth, shifting the microbe into a state of bacteriostasis and resulting in the arrest of microbial proliferation.


Modulation of Host Immunological Response

Beyond its direct effects on bacteria, Azithromycin engages a secondary, non-antimicrobial mechanism by influencing local host cells. The molecule modulates signaling cascades within immune cells, which leads to an attenuation in the release of certain pro-inflammatory cytokines and chemokines at the site of activity. This dampening effect on the local immune response contributes to the modulation of localized physiological responses and influences the host's response to the non-proliferating bacterial presence.

Dosage and Administration Information

How Dazi (Azithromycin) is Used

Dazi is administered via the oral route, including tablets and liquid suspensions, and through controlled intravenous (IV) infusion. Oral dosing typically follows a defined, short-term course administered as a single dose per day. Standard adult regimens often consist of a 5-day course (starting with 500 mg on Day 1, followed by 250 mg on Days 2–5) or a 3-day course (e.g., 500 mg daily), or a single high dose of up to 2 grams for certain conditions.

The relationship to food depends on the specific oral formulation. Standard oral forms may be taken with or without food, whereas the extended-release suspension must be administered on an empty stomach, defined as one hour before or two hours after a meal. Pediatric dosing is determined based on the patient's body weight (mg/kg), which differs from the fixed adult dose.

When the intravenous route is initiated, 500 mg is typically given daily for 1 to 2 days before a transition to the oral form. The IV preparation must be reconstituted and then diluted to a final concentration of 1 mg/ mL or 2 mg/ mL. The final solution must be administered as a slow infusion over 1 to 3 hours and must not be given as a rapid bolus. Instructions for a missed dose generally involve taking it immediately, while avoiding taking a double dose to make up for the omission.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dazi

The information presented here describes the types of clinical research conducted on Azithromycin (Dazi), the findings observed in these studies, and the remaining gaps in the evidence, as reported in official and peer-reviewed scientific sources. The intent is to provide a neutral overview of the research landscape.


Evidence for Use in Respiratory Tract Infections (Upper and Lower)

The evidence base for studying Azithromycin in acute infections of the airways, such as bacterial pneumonia, bronchitis, tonsillitis, and sinusitis, is built mainly on short-term Randomized Controlled Trials (RCTs). Research explored how symptoms evolved during the study period and focused on outcomes related to physical discomfort and systemic or functional imbalance. In these trials, researchers primarily monitored whether the body achieved a microbiological outcome (measured absence of the specific bacteria) and how patient symptoms evolved over a defined time interval. The research highlights changes measured during the short study period, contributing to the broader evidence landscape.


Evidence for Use in Specific Urogenital Infections

Research exploring the use of Azithromycin for certain sexually transmitted infections is often framed as Randomized Controlled Trials (RCTs) that compare a defined study dose of Azithromycin against multi-dose alternatives. The primary focus of these studies was to measure microbiological outcome, defined as the specific pathogen no longer being detected in follow-up lab tests. Studies reported rates of microbiological clearance that were measured in patients focusing on urogenital sites. However, studies exploring infections in certain non-genital anatomical sites, such as the rectum, reported mixed findings regarding pathogen clearance.


Long-Term Studies and Follow-up Duration

While most studies related to acute infections are short-term, Azithromycin was also evaluated in long-term research (often six months to a year or more) for individuals with chronic respiratory conditions such as Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD). In these specific patient groups, studies tracked outcomes related to episodic or acute changes in their condition. Research describes patterns observed in studies related to the frequency of episodic or acute changes (pulmonary exacerbations). The crucial uncertainty in this long-term context relates to the potential for the selection of resistant bacteria.

Frequently Asked Questions (FAQ)

Common questions about Dazi (FAQ)


Q: How long does the effect of Dazi last after taking it?

A: Dazi (azithromycin) has a long terminal half-life of 68 hours, according to official product information. This duration means the drug is taken up by the body’s tissues and released slowly over a long period. This characteristic is described in official documents as supporting the drug's suitability for once-daily administration.


Q: Do the side effects of Dazi get better over time?

A: Regulatory documents primarily focus on documenting the types and frequency of adverse reactions, but do not explicitly state a typical timeline for when common side effects might improve. Individuals with persistent side effects or concerns may wish to consult with a healthcare professional regarding their symptoms.


Q: Is there a maximum time someone can stay on Dazi?

A: The appropriate duration of use for Dazi depends on the specific condition being addressed. Studies documented in regulatory files describe both short-term courses (3-5 days for acute infections) and long-term use (e.g., several months to a year for specific chronic respiratory conditions) but do not define a single maximum time limit for all possible uses.


Q: Does Dazi require regular blood tests or monitoring?

A: Official warnings state that the medicine can cause rare but serious liver damage (hepatotoxicity). Discontinuation is required immediately if signs of hepatitis occur. This indicates that patients should be aware of and look for symptoms that might suggest potential liver damage.


Q: What is the difference between Dazi and a generic version of the same medicine?

A: Regulatory bodies require that generic versions of Azithromycin (the active ingredient in Dazi) use the same active ingredients and work the same way in the body. Therefore, generic forms are required to meet the same regulatory standards for efficacy and safety as the brand-name product, according to official statements.


Q: Why do some people stop taking Dazi?

A: The reasons for discontinuing the medication are often related to adverse reactions. The most commonly reported side effects listed in regulatory documents are gastrointestinal issues like diarrhea and nausea, as well as headache. Discontinuation of the medicine may be necessary in rare situations involving serious adverse events, such as severe allergic reactions or liver dysfunction.


Q: Is Dazi processed by the liver?

A: Yes, regulatory documents indicate that Dazi (azithromycin) is largely eliminated from the body via biliary excretion, which is a process involving the liver. This fact underpins the regulatory caution advised for patients with existing liver impairment.


Q: Can Dazi cause a rash?

A: Official adverse reaction reports list rash as a possible allergic reaction. Additionally, warnings highlight the rare but serious possibility of severe skin reactions, such as Stevens-Johnson Syndrome (SJS), which can sometimes be delayed in onset.


Q: Does Dazi need to be taken at a specific time of day?

A: The medicine is designed to be taken as a single dose per day. While regulatory documents specify the relationship to food (with or without, depending on the formulation), they typically do not require a specific time of day (morning or night) for administration.


Q: What does the term 'contraindication' mean in relation to Dazi?

A: In regulatory language, a contraindication means the medication absolutely must not be used because the risk of harm outweighs any potential benefit. For Dazi, this prohibition applies to any patient with a known history of hypersensitivity to macrolide antibiotics or a prior history of liver damage associated with azithromycin use.


Q: What is the half-life of Dazi?

A: The mean terminal half-life of Dazi (azithromycin) is reported in official pharmacokinetic data as 68 hours.


Q: How quickly does Dazi usually start working?

A: The medicine’s mechanism involves rapidly halting bacterial protein synthesis. While patient response varies, the timeline for potential symptom improvement is generally described in relation to the first couple of days of treatment.


Q: Is it common to feel tired when starting Dazi?

A: Official regulatory documents list fatigue (feeling tired) as a reported adverse reaction. Individuals are advised to be aware of how they react to the medicine when performing activities that require concentration.


Q: Is Dazi known to interact with commonly used over-the-counter pain relievers?

A: Official guidance indicates that Dazi is generally considered safe to be used alongside common over-the-counter pain relievers such as ibuprofen or acetaminophen. There is no direct, serious drug-drug interaction expected between these products.


Q: Is it safe to drive or operate machinery while taking Dazi?

A: Adverse reaction reports documented in official labeling include nervous system effects such as dizziness, vertigo, and somnolence (drowsiness). Individuals are advised to determine their response to the medicine before engaging in activities that require full mental alertness.


Q: Can Dazi affect sleep patterns?

A: Yes, insomnia (difficulty sleeping) is included among the reported adverse reactions in official regulatory documents.


Q: Does Dazi work differently for men and women?

A: Pharmacokinetic studies cited in official labeling found no significant difference in how the drug is processed and eliminated by the body between male and female subjects.


Q: Does Dazi interact with alcohol?

A: Official patient guidance indicates there is no direct chemical interaction that prevents the medicine from working. However, consuming alcohol can potentially worsen common gastrointestinal side effects and is generally advised to be avoided.


Q: Can Dazi affect mood?

A: Yes, post-marketing reports documented in official regulatory sources include psychiatric adverse reactions such as agitation and nervousness.

How should Dazi be stored and disposed of?

How to Store and Dispose of Dazi

Storage rules for Dazi (azithromycin) depend on the dosage form. Tablets and the dry powder for suspension must be stored at controlled room temperature (e.g., 15 C to 30 C), kept in a tightly closed container away from excess moisture.

Stability and Handling

The standard oral suspension is stable for 10 days after reconstitution and must then be discarded; this liquid suspension must not be frozen. All forms of Dazi must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal

Unused or expired medicine, including any leftover liquid suspension, must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dazi found in:

A-Z Index: